FDA Holds Hearing on Psychedelics as Optimi Health Advances MDMA Trial for PTSD
The U.S. Food and Drug Administration (FDA) held a public hearing in September 2026 to discuss the potential therapeutic use of psychedelic drugs, following an executive order by President Donald Trump aimed at accelerating research into these treatments for serious mental illnesses like PTSD. This development coincides with Optimi Health Corp.'s progress on its MDMA-assisted therapy trial for veterans and frontline workers, which is set to begin in 2027 under a Canadian regulatory framework. Optimi Health, based in Canada, has expanded production of pharmaceutical-grade MDMA capsules and supplies them globally. The company plans to conduct Phase 3 clinical trials involving up to 100 participants after receiving authorization from Health Canada. In May 2026, Optimi completed a $15 million public offering as it listed on the Nasdaq. Elon Musk's past advocacy for psychedelics has drawn attention to this sector. He previously stated that these substances could significantly improve mental health outcomes and urged serious consideration of their potential.
Topics: FDA hearing MDMA therapy psychedelics PTSD treatment